Research using ultra-widefield imaging showed that assessment of the entire retina is important to more accurately stratify disease progression risk in vulnerable patients.
Patients taking GLP-1 agonists had a higher rate of progression to proliferative retinopathy and new-onset macular edema than those on SGLT-2 inhibitors.
Patients with low glomerular filtration rates and high glycated hemoglobin levels fared worse in this study, highlighting the need for continuous monitoring of systemic health.